Biotechs are Back in Favor Amid Plethora of Positive Developments
Published: Sep 24, 2013
It isn’t often that the biotechnology industry gets swamped with plenty of good news, but that’s what has been happening in recent months. Not surprisingly, they have attracted investor interest. A number of new drug approvals, affirmative data, and accelerated sales and earnings growth at the big biotech companies have re-focused attention to the industry. And increased activity in mergers-and-acquisition front has added to the sector’s allure. A robust M&A environment, a key ingredient for a sustainable biotech bull market rally, has helped drive up the price of many biotech stocks.
Hey, check out all the research scientist jobs. Post your resume today!